吡啶斯的明
溴化吡啶斯的明是一種合成的季銨類抗膽鹼酯酶藥物，在獸醫學中主要用於控制犬（偶爾用於貓）的**重症肌無力 (Myasthenia Gravis, MG)**。 * **臨床要點：** 由於其季銨結構，吡啶斯的明在標準治療劑量下不易穿透血腦屏障。這使其非常適合針對如重症肌無力等周邊神經肌肉接合處疾病，而不會引起明顯的中樞神經系統 (CNS) 副作用。 * 通常認為它對**後天性重症肌無力**的療效遠優於先天性。 * 由於其吸收不穩定且治療指數狹窄，必須根據療效仔細調整劑量，在改善肌肉力量與膽鹼能毒性風險之間取得平衡。
作用機制: **Pyridostigmine** acts as a reversible, competitive inhibitor of the enzyme **acetylcholinesterase (AChE)** at the neuromuscular junction. * **Mechanism:** Pyridostigmine competes directly with **acetylcholine (ACh)** for attachment to AChE. The resulting pyridostigmine-AChE complex is hydrolyzed much more slowly than the natural ACh-AChE complex. * **Pathway:** Inhibition of AChE → Decreased breakdown of ACh → Accumulation of ACh in the synaptic cleft → Prolonged and increased stimulation of **nicotinic ACh receptors** on the motor endplate → Enhanced skeletal muscle contraction and improved strength in myasthenic patients.
各物種劑量
- Myasthenia gravis (MG) · 0.5-3 mg/kg daily PO in divided doses · PO · Divided daily · Dose depending on response.
- Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h · PO · q8-12h
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO per day · PO · Daily · Given with corticosteroids.
- Myasthenia gravis · 0.25 mg/kg · PO · q8-12h
- Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h. For animals that cannot tolerate oral medications, it may be used as an IV constant rate infusion at 0.01-0.03 mg/kg/hour. · PO/IV · q8-12h or CRI · Titrate to effect to minimize adverse effects and maximize muscle strength.
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO q8-12 hours with food. · PO · q8-12h · Start low and increase slowly. Liquid formulation recommended for easy adjustment. An H2 antagonist (e.g., famotidine 5 mg/kg/day) may reduce nausea/GI irritation.
- Acquired Myasthenia gravis (MG) · 7.5-30 mg PO two times a day. · PO · BID · Begin after oral regurgitation is abolished with parenteral neostigmine. Once stable, begin corticosteroids for 2 weeks, then gradually reduce pyridostigmine.
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO two to three times a day. · PO · BID-TID · If no response, add prednisone.
- Myasthenia gravis (MG) · 0.5-1 mg/kg PO two to three times a day · PO · BID-TID · With or without prednisone (2 mg/kg PO twice daily). Spontaneous remission is not uncommon.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新藥品仿單及個別病患確認。
給藥途徑
禁忌症
- Hypersensitivity to anticholinesterase compounds or bromides
- Mechanical or physical obstructions of the urinary tract
- Mechanical or physical obstructions of the gastrointestinal (GI) tract
- Mechanical gastrointestinal obstruction
- Mechanical urinary tract obstruction
- Peritonitis
不良反應
- Nausea
- Vomiting
- Diarrhea
- Excessive salivation (ptyalism)
- Sweating (in species with sweat glands)
- Increased bronchial secretions
- Bronchospasm
- Pulmonary edema
- Respiratory paralysis
- Miosis (pupil constriction)
- Blurred vision
- Lacrimation (tearing)
- Bradycardia
- Tachycardia
- Cardiospasm
- Hypotension
- Cardiac arrest
藥物相互作用
- Atropine · Antagonizes the muscarinic effects of pyridostigmine. Use cautiously as it can mask early clinical signs of a life-threatening cholinergic crisis.
- Corticosteroids · May decrease the anticholinesterase activity of pyridostigmine. Discontinuing corticosteroids may suddenly increase anticholinesterase activity, requiring dose adjustments.
- Dexpanthenol · Theoretically may have additive cholinergic effects when used concurrently.
- Neuromuscular blocking drugs (e.g., aminoglycosides) · May necessitate increased dosages of pyridostigmine when treating or diagnosing myasthenic patients.
- Magnesium (parenteral) · Can antagonize anticholinesterase therapy due to its direct depressant effect on skeletal muscle.
- Muscle Relaxants · May prolong the Phase I block of depolarizing muscle relaxants (e.g., succinylcholine) and antagonize the actions of non-depolarizing agents (e.g., pancuronium, atracurium).
- Aminoglycosides · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Clindamycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Lincomycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Propranolol · May antagonize the effects of pyridostigmine · moderate
- Suxamethonium · Pyridostigmine may enhance the effect of depolarizing muscle relaxants · major
監測
- Clinical signs of cholinergic toxicity (salivation, lacrimation, urination, defecation, GI upset, emesis, weakness)
- Efficacy of therapy (improvement in muscle strength, reduction of megaesophagus/regurgitation)
- Respiratory rate and effort
- Improvement in muscle strength and exercise tolerance
- Signs of muscarinic toxicity (hypersalivation, vomiting, diarrhea, miosis)
- Heart rate and rhythm
- Respiratory rate and effort (especially in patients with megaoesophagus)
過量
Overdosage of pyridostigmine can induce a life-threatening **cholinergic crisis**. * **Clinical Signs (SLUDGE syndrome):** GI effects (nausea, vomiting, diarrhea), excessive salivation, sweating, respiratory distress (increased bronchial secretions, bronchospasm, pulmonary edema, respiratory paralysis), ophthalmic effects (miosis, blurred vision, lacrimation), cardiovascular collapse (bradycardia, tachycardia, hypotension, cardiac arrest), severe muscle cramps, and profound weakness. * **Diagnostic Challenge:** Overdoses in myasthenic patients can be very difficult to distinguish from a **myasthenic crisis** (disease exacerbation). The time of onset of clinical signs or an **edrophonium challenge** (Tensilon test) may help differentiate the two. * **Treatment:** Consists of immediate respiratory and cardiac supportive therapy. **Atropine** should be administered to antagonize muscarinic effects (refer to atropine protocols for cholinergic toxicity).
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。